

## Parkinson's Disease Therapeutics Market Size Is Expected to Reach Around USD 5.28 Bn to Reach at 22.95% CAGR by 2025

Parkinson's disease therapeutics market USD 2.61 bn in 2018 & is expected to generate around USD 5.28 bn by 2025, at a CAGR of around 10.6% between 2019 & 2025.



Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion), and by Distribution Channel (Hospital



Global Parkinson's disease therapeutics market is expected to generate around USD 5.28 billion by 2025, at a CAGR of around 10.6% between 2019 and 2025."


Zion Market Research

Pharmacy, Retail Pharmacy, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025". According to the report, the global Parkinson's disease therapeutics market was approximately USD 2.61 billion in 2018 and is expected to generate around USD 5.28 billion by 2025, at a CAGR of around 10.6% between 2019 and 2025.


Parkinson's disease (PD) is a nervous system disorder that increases in severity with time. The disease is characterized by bradykinesia, rigidity, tremor, and postural instability.

Some of the most common symptoms of Parkinson's disease include arm, hand, or leg tremors, problems associated with balancing and walking, stiff muscles, and slow physical movements. Other symptoms include constipation, trouble swallowing, dementia, fixed or blank expressions, and speech disabilities. The global Parkinson's disease therapeutics market is likely to be driven by the increasing research and development activities for the development of novel Parkinson's disease therapeutic drugs and rising Parkinson's disease incidences.

- -The 2022 revised study includes a detailed industry analysis, introduction, and overview.
- -The package contains the COVID-19 Pandemic Outbreak Impact Analysis.
- -nearly 227 pages Report on Research (Including Recent Research)
- -Give comprehensive chapter-bychapter instructions on the Request
- -Graphical Representation of Size, Share, and Trends for the Year 2022 for the Updated Regional Analysis
- -Includes The updated tables and figures



Parkinson's Disease Therapeutics Market Size



Parkinson's Disease Therapeutics Market Share

- -The Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis are all included in the most recent version of the study.
- -Market research techniques from Zion

As per the Parkinson's Foundation, around 8 to 10 million people worldwide are affected by Parkinson's disease, and every year approximately 70,000 Americans are diagnosed with it.

Based on drug class, the market includes dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors, anticholinergic drugs, levodopa combination, monoamine oxidase B (MAO-B) inhibitors, and others. The levodopa combination segment held a major share of the global market in 2018, as the levodopa combination therapy is among the highly effective treatments for controlling motor symptoms at different stages of Parkinson's disease.

Based on the route of administration, the market includes transdermal, oral, subcutaneous, and intestinal infusion. The oral segment held a significant share of the global market in 2018. Additionally, the introduction of Duopa medicine in the U.S. contributed to a major share of the intestinal infusion segment in the global market.

The distribution channel of the Parkinson's disease therapeutics market is fragmented into retail pharmacy, online sales, and hospital pharmacy. The retail pharmacy segment dominated the

global market in 2018 and is projected to hold a significant market share in the future.

## 

By region, Europe holds a major share of the global Parkinson's disease therapeutics market followed by the North American region. Favorable medical reimbursement policies, rising funding and grants for research, high Parkinson's disease prevalence, and growing awareness about the disease are contributing to the European Parkinson's disease therapeutics market. In the North American market, alone there are more than 10 different drugs under phase III clinical pipeline studies for treating different symptoms of Parkinson's disease in the U.S. alone. The Asia Pacific Parkinson's disease therapeutics market is likely to show a moderate CAGR, owing to a large base of the elderly population suffering from Parkinson's disease, particularly in China and Japan.

Teva Pharmaceutical
STADA Arzneimittel
Impax Laboratories
Novartis F.
Hoffmann-La Roche Merck & Co.
UCB Inc.
GlaxoSmithKline AbbVie
Valeant Pharmaceuticals International.

Levodopa Combination
Dopamine Agonists
Monoamine Oxidase B (Mao-B) Inhibitors
Anticholinergic Drugs
Catechol-O-Methyltransferase (COMT) Inhibitors
Others

Oral

Transdermal
Subcutaneous
Intestinal Infusion

Hospital Pharmacy Retail Pharmacy Online Sales

North America

The U.S.

Europe

IJK

France

Germany

Asia Pacific

China

Japan

India

Latin America

Brazil

The Middle East and Africa

https://www.zionmarketresearch.com/report/parkinsons-disease-therapeutics-market

What different growth factors are influencing the market?

- -Which geographic areas will have a significant impact on the market's expansion
- -What technological improvements and current innovations have been made in the market?

What new trends are you seeing in the market?

What impact has COVID-19 had on the market?

What will the market look like after the pandemic?

What are the main dangers that the market's growth prospects face?

DDDD DDDD@https://www.zionmarketresearch.com/news/parkinsons-disease-therapeutics-market

a comprehensive examination of the parent market

significant alterations in market dynamics

Market segmentation information

Market study in terms of volume and value from the past, present, and future

Evaluation of developments in specialist industries

Analyses of market shares

crucial tactics used by important players

regional marketplaces and emerging segments

Healthcare Business Intelligence (BI) Market

https://www.einpresswire.com/article/594128807/global-healthcare-business-intelligence-bi-market-analysis-to-accounted-for-value-around-usd-10-117-mn-by-2025

https://www.linkedin.com/pulse/global-colorants-market-research-report-covers-future-jon-sena/

https://www.linkedin.com/pulse/global-bioethanol-market-passenger-cars-2022-worldwide-jon-sena/

DNA and Gene Chips@https://www.openpr.com/news/2760082/global-dna-and-gene-chips-market-industry-trends-size-scope

Kajal Rupnar Zion Market Research + +18554654651 ext. email us here Visit us on social media: Facebook **Twitter** LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/595097916

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.